Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Pharma
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL
BMS' Breyanzi is the first CAR-T to deliver a positive readout in CLL in a pivotal multicenter study. Still, its path at the FDA remains uncertain.
Angus Liu
May 25, 2023 5:00pm
Novartis targets new fields—and CAR-T—for immunology growth
May 10, 2023 5:00pm
Astellas, J&J, Sun and more—Fierce Pharma Asia
May 5, 2023 8:55am
Danaher's Aldevron unit plots mRNA manufacturing expansion
May 1, 2023 12:57pm
BioMarin debuts €38M expansion of its Irish operations
Apr 25, 2023 9:05am
J&J-Legend, BeiGene-Novartis and more—Fierce Pharma Asia
Apr 21, 2023 9:15am
More News
Leaked abstract shows massive benefit for J&J, Legend's Carvykti
Apr 19, 2023 9:31am
J&J, Legend tap Novartis to help make CAR-T therapy Carvykti
Apr 14, 2023 11:42am
Takeda, Astellas, Eisai—Fierce Pharma Asia
Apr 14, 2023 8:25am
Vertex, bluebird SCD gene therapies can cost $1.9M: ICER
Apr 13, 2023 11:33am
See more stories
